Propyphenazone is commonly used across conditions presenting with acute episodes, relevant when supportive symptom management is appropriate for symptoms that interfere with daily functioning. This medication is applied across domains where additional symptomatic support is needed.

It helps address symptom clusters that may become more disruptive during flare-ups in the head, muscles, or joints. Propyphenazone is applied in scenarios where additional management of discomfort is required for symptoms related to physical discomfort, such as headaches, muscle aches, and symptoms related to systemic imbalance. It is also applicable in clinical settings that involve episodic or fluctuating manifestations, such as minor post-injury discomfort or menstrual cramping.

“It provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.”

This medication assists with maintaining functional stability and supports general well-being during symptomatic phases by helping to moderate distressing manifestations.

Quick Fact: The medicine is relevant in contexts involving heightened systemic burden.

Who Can and Cannot Use Propyphenazone?

Eligibility for Propyphenazone is strictly determined by its classification as a pyrazolone derivative Non-Steroidal Anti-Inflammatory Drug (NSAID), which carries specific regulatory restrictions.

Populations That Must Not Use Propyphenazone

Propyphenazone is contraindicated and must not be used by individuals with:

• Hypersensitivity: Known allergy to Propyphenazone, other pyrazolone derivatives (e.g., phenazone), or any related NSAIDs.
• Severe Organ Failure: Patients with severe hepatic failure, severe renal failure, or active gastrointestinal ulcers or bleeding.
• Blood Disorders: Individuals with bone marrow deficiencies or a history of specific blood disorders, due to the drug class's associated risk.
• Metabolic Conditions: Patients with acute hepatic porphyria or glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Age and Reproductive Restrictions

The medicine is generally contraindicated during the third trimester of pregnancy and is not recommended for nursing mothers.

Usage is typically contraindicated in children under 12 years of age and is primarily reserved for adults and adolescents over this threshold. Older adults require special caution and often medical supervision.

Interactions with other medicines and products

The interaction profile for Propyphenazone, a pyrazolone derivative, is established based on its function as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and its common inclusion in combination products.

Contraindications and Restrictions

Propyphenazone is formally contraindicated for co-administration with other pyrazolone derivatives such as Metamizol, Aminophenazone, or Phenylbutazone due to the documented risk of cross-hypersensitivity reactions.

Pharmacodynamic Risks

Official regulatory documents highlight pharmacodynamic interactions that increase the risk of bleeding. Co-administration with Anticoagulants (e.g., Warfarin) is classified as a clinically significant interaction that enhances the anticoagulant effect. Similarly, concurrent use of other NSAIDs increases the potential for additive gastrointestinal adverse effects.

Pharmacokinetic Modifications

The product's systemic exposure can be modified by metabolic interactions. Hepatic enzyme inhibitors like Cimetidine may increase Propyphenazone plasma levels, while Hepatic enzyme inducers (e.g., Rifampicin, Barbiturates) may accelerate its clearance. A distinct pharmacokinetic interaction is documented with Paracetamol (Acetaminophen), which increases Propyphenazone’s peak blood plasma concentration and prolongs its elimination time. Furthermore, use with Alcohol carries an increased risk of hepatotoxicity, especially within combination formulations. This profile requires heightened awareness for populations such as Elderly Patients.

Primary Mechanism: COX Enzyme Inhibition

Propyphenazone acts as a non-selective inhibitor of the Cyclooxygenase (COX-1 and COX-2) enzymes. This molecular interaction blocks the conversion of arachidonic acid into pro-inflammatory mediators, primarily prostaglandins ( PGE2). This action initiates the drug's core mechanistic cascade, which modulates specific physiological responses.

---

Systemic Physiological Modulation

Reduced peripheral PGE2 synthesis lessens the sensitization of nociceptors (pain-sensing neurons), influencing afferent pain signaling. Concurrently, the inhibition of PGE2 synthesis within the hypothalamus affects the central thermoregulatory set-point, resulting in the normalization of elevated body temperature. This highlights the drug's simultaneous action across both peripheral and central pathways.

---

Secondary Target: TRPA1 Channel

A distinct mechanism involves Propyphenazone's inhibitory action on the Transient Receptor Potential Ankyrin 1 ( TRPA1) ion channel. Modulating this sensory channel on specific neurons influences nociception (pain detection), which contributes to the drug's overall mechanistic action profile independent of prostaglandin inhibition.

Administration Guidelines

Propyphenazone is administered according to schedules that define the route, dosage limits, and duration of use. The medicine is primarily available in oral forms, such as tablets, with suppositories existing as an alternate route for rectal use. It is often provided as a fixed-dose combination product with other active ingredients.

Dosing and Administration Schedule

The medicine is structured for as-needed (PRN) use for symptomatic relief, rather than as a continuous daily therapy. Administration is limited to a maximum frequency, and the use is designated for a specific time limit.

Usage Constraint	Specification (Propyphenazone component)
Adult Single Dose	1 to 2 tablets (corresponding to 150 mg to 300 mg of Propyphenazone).
Maximum Daily Frequency	Not to exceed three single doses in a 24-hour period.
Course Duration	Use is limited to short-term only, typically not more than one week.
Adolescent Single Dose	The dose for adolescents aged 12–16 years is specified as 1 tablet (150 mg).

Oral dosage forms are taken with ample water or fluid. Tablets are not to be broken, chewed, or crushed. Due to the nature of fixed-dose combination products, there is a procedural condition regarding the avoidance of simultaneous use with other medicines containing Paracetamol.

Research Evidence / Overview of Studies for Propyphenazone

Research Evidence for Acute Pain Relief

Propyphenazone research explored outcomes related to physical discomfort, particularly in conditions associated with acute or disruptive episodes. The main body of evidence was evaluated in Randomized Controlled Trials (RCTs) and subsequent pooled statistical analyses of multiple trials, which were used to examine how symptom intensity changes over short, defined time intervals. Study outcomes examined measures such as overall pain relief scores and the time required for any observed change in pain perception to begin.

The primary populations evaluated in this research include Adults who developed acute, moderate to severe pain, frequently was observed in standardized research models such as post-dental surgery pain. Data show patterns related to the outcomes measured being assessed over a very short-term follow-up duration, typically concentrated within a few hours following administration. The evidence contributes to the broader evidence landscape used for understanding symptom patterns during these phases of heightened symptom activity.

---

Comparative Evidence: Propyphenazone in Combination Formulas

Propyphenazone was studied for use in combination with other active ingredients, and this combination research forms a substantial part of the available evidence. Regulatory reviews of this evidence describe patterns where the combination formulas were observed in some studies to differ in measurement patterns compared to placebo, and to other single-agent pain relievers used as comparators in the trials. The research focused on outcomes related to episodic or acute changes and studies observing responses over defined time intervals.

---

Long-Term Data and Follow-Up Duration

Studies for Propyphenazone primarily focused on research exploring short-term symptom changes and research examining temporary physiological imbalance, consistent with the condition frames used in research for conditions associated with acute or disruptive episodes. Follow-up durations were limited across the key trials, and outcome measurements were concentrated within the immediate hours following dosing.

Long-term effects are not fully established and data are still emerging. There is limited information for long-term outcomes, and research provides limited insight into the durability of any observed symptom change beyond the initial follow-up period. The available evidence generally reflects the specific conditions under which the acute studies were conducted.

---

Areas of Research Uncertainty and Gaps

Data for certain groups remain insufficient. For instance, the research exploring the evidence for Propyphenazone in populations such as children, older adults, or individuals with certain pre-existing conditions is limited. Subgroup findings are uncertain, as the results apply only to the populations studied in the acute pain models.

Furthermore, while Propyphenazone was studied for outcomes related to systemic or functional imbalance (e.g., fever reduction), comparative evidence is lacking regarding this specific action, and data for certain groups remain insufficient. These gaps indicate areas where certainty remains low. Study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. WHO ATC/DDD Index: N02BB54 (Propyphenazone, combinations excl. psycholeptics)

Common questions about Propyphenazone (FAQ)

---

Q: What is propyphenazone used for?

According to the official product information, propyphenazone is used primarily to relieve pain and reduce fever. It is commonly indicated for headaches, toothaches, and menstrual pain. It belongs to a group of medicines known as non-steroidal anti-inflammatory drugs (NSAIDs) with pain-relieving and fever-reducing characteristics.

---

Q: Can propyphenazone be taken with alcohol?

Regulatory documents state that using propyphenazone simultaneously with alcohol is not recommended. This combination may increase the risk of certain side effects, such as dizziness, and could potentially increase irritation in the stomach. This potential interaction is mentioned in the official product information.

---

Q: How long does propyphenazone take to work?

Studies and official information indicate that propyphenazone is absorbed quite rapidly following administration. The onset of pain relief, based on studies, is often reported to begin within approximately 30 minutes. The specific time to peak effect may vary slightly depending on the individual.

---

Q: Is it safe to use Propyphenazone while breastfeeding?

According to the official product information and regulatory documents, it is advised against using propyphenazone while breastfeeding. This is a precaution because the active substance has the potential to pass into the breast milk. Regulatory warnings indicate that anyone who is breastfeeding should review their situation with a qualified healthcare professional.

How to Store and Dispose of Propyphenazone: Official Regulatory Information

Official regulatory documents define strict conditions for the storage and disposal of Propyphenazone to maintain its stability and prevent environmental contamination.

Storage and Handling Requirements

Condition	Requirement
Temperature	Store in a cool place, generally below 25 C (77 F).
Protection	Keep the substance in a dry place and protect from light.
Container	Keep containers tightly closed and away from strong oxidizing agents.

Disposal Instructions

Propyphenazone must not be disposed of with household garbage or allowed to enter sewer systems, drains, or the environment. Disposal must be conducted according to local, regional, and national regulations, typically by a licensed chemical waste disposal facility or controlled incineration. This prevents environmental contamination.